Seller record · Telehealth service

Nexlife

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published. The home page says the compounding pharmacies perform quality-control testing, with no report behind the claim.

At a glance

NexlifeTelehealth service

7/8criteria passed

Price: Semaglutide $139 a month, or from $119 on a 12-month plan; tirzepatide $169, or from $139
Sells: compounded semaglutide, compounded tirzepatide
FDA letters: 1 on file

Visit Nexlife See all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A telehealth and care-coordination platform selling compounded semaglutide and tirzepatide at one price for every dose, with a nutrition plan and a fitness coaching call included and care from an affiliated medical group. Care starts with an online assessment, its product pages name three filling pharmacies, and an FDA warning letter names its operating company.

Operating entity Nexlife Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Nexlife's telehealth consent; Nexlife's semaglutide all plans page
S2	Prescription gating	PASS	Nexlife's website; Nexlife's semaglutide all plans page
S3	Pharmacy identification	PASS	Nexlife's semaglutide all plans page; Nexlife's tirzepatide all plans page
S4	Compounding disclosure	PASS	Nexlife's website; Nexlife's semaglutide all plans page; Nexlife's frequently asked questions page
S5	Analytical documentation	FAIL	Nexlife's website; Nexlife's important safety information page; Nexlife's terms and conditions
S6	Business address	PASS	Nexlife's contact page; Nexlife's privacy policy
S7	Price disclosure	PASS	Nexlife's semaglutide all plans page; Nexlife's tirzepatide all plans page; Nexlife's website
S8	Enforcement status	PASS	FDA's website; FDA warning letter 730096

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSClinical services are provided by Nexlife Medical Group P.C. and its affiliated professional entities, whose providers, licensed in the patient's state, review each assessment and may prescribe, adjust, pause or decline treatment.Source: Nexlife's telehealth consent; Nexlife's semaglutide all plans page.

S2PASSThe home and plan pages list an online assessment of health history and goals as the first step, reviewed by a licensed provider who decides whether treatment is appropriate before any prescription ships, and the start buttons point to that assessment.Source: Nexlife's website; Nexlife's semaglutide all plans page.

S3PASSThe disclosures on the plan pages say prescriptions are filled by Absolute Pharmacy in Lutz, Florida, Premium Compounding in Decatur, Alabama, and Boudreaux's New Drug Store in Lake Charles, Louisiana, depending on the patient's location.Source: Nexlife's semaglutide all plans page; Nexlife's tirzepatide all plans page.

S4PASSThe home page, the plan pages and the answers state that compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality, and that compounded semaglutide and tirzepatide are not the brand-name drugs.Source: Nexlife's website; Nexlife's semaglutide all plans page; Nexlife's frequently asked questions page.

S5FAILNo certificate of analysis or lot document is published. The home page says the compounding pharmacies perform quality-control testing, with no report behind the claim.Source: Nexlife's website; Nexlife's important safety information page; Nexlife's terms and conditions.

S6PASSNexlife Inc. at 260 Newport Center Dr, Newport Beach, CA 92660, printed as the office on the contact page and as the mailing address in the privacy policy.Source: Nexlife's contact page; Nexlife's privacy policy.

S7PASSCompounded semaglutide at $139 a month on the monthly plan, or $132, $125 or $119 a month on 3, 6 or 12-month plans, and compounded tirzepatide at $169 a month, or $159, $149 or $139, the same price at every dose with shipping, provider visits and coaching included. The home page gives the program as low as $119 a month on a 12-month plan.Source: Nexlife's semaglutide all plans page; Nexlife's tirzepatide all plans page; Nexlife's website.

S8PASSFDA warning letter 730096, June 2026, names Nexlife Inc. doing business as Nexlife at the Newport Beach, California address the site prints, and it reviewed the seller's own website. It alleges that pictured labels identify Nexlife as the compounder of its semaglutide and tirzepatide products when it is not. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 730096.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 730096, issued June 2026, to Nexlife Inc. dba NexlifePictured labels identify Nexlife as the compounder of semaglutide and tirzepatide products when it is not, which misbrands the products.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Nexlife

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.